Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis - PubMed (original) (raw)
Clinical Trial
. 2004 Feb 1;189(3):440-9.
doi: 10.1086/381128. Epub 2004 Jan 26.
Affiliations
- PMID: 14745701
- DOI: 10.1086/381128
Clinical Trial
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis
Frederick G Hayden et al. J Infect Dis. 2004.
Abstract
We determined the efficacy of postexposure prophylaxis (PEP) and treatment of ill index cases with oseltamivir, in an attempt to prevent influenza transmission in households, in a study conducted in 277 households with 298 index cases (62% with laboratory-confirmed influenza) and 812 contacts aged > or =1 year. Contacts were randomized by household to receive treatment (5 days; n=402), if illness developed, or PEP for 10 days (n=410), and the number of households with at least 1 contact developing laboratory-confirmed influenza was measured. PEP provided a protective efficacy of 58.5% (95% confidence interval [CI], 15.6%-79.6%; P=.0114) for households against proven influenza and 68.0% (95% CI, 34.9%-84.2%; P=.0017) for individual contacts, compared with treatment of index cases alone. No oseltamivir-resistant variants were detected in treated index cases or contacts. PEP of household contacts of those with influenza reduces the secondary spread of influenza in families when the initial household case is treated.
Comment in
- Postexposure prophylaxis with oseltamivir reduced influenza transmission in households.
Gross PA. Gross PA. ACP J Club. 2004 Sep-Oct;141(2):40. ACP J Club. 2004. PMID: 15341460 No abstract available.
Similar articles
- Risk factors of influenza transmission in households.
Viboud C, Boëlle PY, Cauchemez S, Lavenu A, Valleron AJ, Flahault A, Carrat F. Viboud C, et al. Br J Gen Pract. 2004 Sep;54(506):684-9. Br J Gen Pract. 2004. PMID: 15353055 Free PMC article. - Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
Talbird SE, Brogan AJ, Winiarski AP. Talbird SE, et al. Am J Prev Med. 2009 Nov;37(5):381-8. doi: 10.1016/j.amepre.2009.08.012. Am J Prev Med. 2009. PMID: 19840692 - Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households.
Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C. Monto AS, et al. J Infect Dis. 2002 Dec 1;186(11):1582-8. doi: 10.1086/345722. Epub 2002 Nov 6. J Infect Dis. 2002. PMID: 12447733 Clinical Trial. - Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment.
Gillissen A, Höffken G. Gillissen A, et al. Med Microbiol Immunol. 2002 Dec;191(3-4):165-8. doi: 10.1007/s00430-002-0139-9. Epub 2002 Sep 12. Med Microbiol Immunol. 2002. PMID: 12458353 Review. - Oseltamivir for influenza.
[No authors listed] [No authors listed] Drug Ther Bull. 2002 Dec;40(12):89-91. Drug Ther Bull. 2002. PMID: 12613182 Review.
Cited by
- AMMI Canada 2023 update on influenza: Management and emerging issues.
Harrison R, Mubareka S, Papenburg J, Schober T, Allen UD, Hatchette TF, Evans GA. Harrison R, et al. J Assoc Med Microbiol Infect Dis Can. 2023 Nov 29;8(3):176-185. doi: 10.3138/jammi-2023-07-12. eCollection 2023 Nov. J Assoc Med Microbiol Infect Dis Can. 2023. PMID: 38058499 Free PMC article. No abstract available. - A Review of the Ring Trial Design for Evaluating Ring Interventions for Infectious Diseases.
Butzin-Dozier Z, Athni TS, Benjamin-Chung J. Butzin-Dozier Z, et al. Epidemiol Rev. 2022 Dec 21;44(1):29-54. doi: 10.1093/epirev/mxac003. Epidemiol Rev. 2022. PMID: 35593400 Free PMC article. - Antiviral Drugs in Influenza.
Świerczyńska M, Mirowska-Guzel DM, Pindelska E. Świerczyńska M, et al. Int J Environ Res Public Health. 2022 Mar 4;19(5):3018. doi: 10.3390/ijerph19053018. Int J Environ Res Public Health. 2022. PMID: 35270708 Free PMC article. Review. - Pathophysiological effects of Tamiflu on liver and kidneys of male rats.
Abdel-Ghaffar WH, Abdelghffar EA. Abdel-Ghaffar WH, et al. Beni Suef Univ J Basic Appl Sci. 2022;11(1):15. doi: 10.1186/s43088-021-00189-6. Epub 2022 Jan 25. Beni Suef Univ J Basic Appl Sci. 2022. PMID: 35097134 Free PMC article. - Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance.
Chaturvedi S, Vasen G, Pablo M, Chen X, Beutler N, Kumar A, Tanner E, Illouz S, Rahgoshay D, Burnett J, Holguin L, Chen PY, Ndjamen B, Ott M, Rodick R, Rogers T, Smith DM, Weinberger LS. Chaturvedi S, et al. Cell. 2021 Dec 9;184(25):6022-6036.e18. doi: 10.1016/j.cell.2021.11.004. Epub 2021 Nov 10. Cell. 2021. PMID: 34838159 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous